Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.
Data from the OPTIC 48-week off-treatment follow-up period demonstrated that 56% of participants who received teprotumumab-trbw (Tepezza, Horizon Therapeutics) and were proptosis responders at week 24 in the OPTIC trial maintained their proptosis response at week 72 without receiving additional thyroid eye disease treatment. In a second study, OPTIC-X, 89% of
Uncategorized